FR2896157B1 - Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. - Google Patents

Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.

Info

Publication number
FR2896157B1
FR2896157B1 FR0600342A FR0600342A FR2896157B1 FR 2896157 B1 FR2896157 B1 FR 2896157B1 FR 0600342 A FR0600342 A FR 0600342A FR 0600342 A FR0600342 A FR 0600342A FR 2896157 B1 FR2896157 B1 FR 2896157B1
Authority
FR
France
Prior art keywords
combination
insulin secretion
triazine derivatives
stimulation agents
secretion stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0600342A
Other languages
English (en)
Other versions
FR2896157A1 (fr
Inventor
Gerard Moinet
Daniel Cravo
Didier Mesangeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0600342A priority Critical patent/FR2896157B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to US12/160,637 priority patent/US8227465B2/en
Priority to SI200631268T priority patent/SI1971339T1/sl
Priority to AU2006334731A priority patent/AU2006334731B2/en
Priority to PT06829703T priority patent/PT1971339E/pt
Priority to AT06829703T priority patent/ATE540682T1/de
Priority to ES06829703T priority patent/ES2378469T3/es
Priority to EA200801665A priority patent/EA016649B1/ru
Priority to JP2008549780A priority patent/JP5702911B2/ja
Priority to EP06829703A priority patent/EP1971339B1/fr
Priority to PCT/EP2006/012182 priority patent/WO2007079914A2/fr
Priority to CNA2006800507984A priority patent/CN101355949A/zh
Priority to KR1020087019388A priority patent/KR20080091366A/ko
Priority to DK06829703.5T priority patent/DK1971339T3/da
Priority to BRPI0620923-8A priority patent/BRPI0620923A2/pt
Priority to CA2636837A priority patent/CA2636837C/fr
Priority to PL06829703T priority patent/PL1971339T3/pl
Priority to ARP070100136A priority patent/AR059030A1/es
Publication of FR2896157A1 publication Critical patent/FR2896157A1/fr
Priority to IL192596A priority patent/IL192596A/en
Priority to ZA200806938A priority patent/ZA200806938B/xx
Application granted granted Critical
Publication of FR2896157B1 publication Critical patent/FR2896157B1/fr
Priority to CY20121100133T priority patent/CY1112674T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
FR0600342A 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. Expired - Fee Related FR2896157B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0600342A FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
BRPI0620923-8A BRPI0620923A2 (pt) 2006-01-13 2006-12-18 composição farmacêutica compreendendo derivados de triazina, uso de um estimulador da secreção de insulina e kit
DK06829703.5T DK1971339T3 (da) 2006-01-13 2006-12-18 Kombination af triazinderivater og insulinsekretionsstimulatorer
PT06829703T PT1971339E (pt) 2006-01-13 2006-12-18 Combinação de derivados de triazina e de estimuladores da secreção de insulina
SI200631268T SI1971339T1 (sl) 2006-01-13 2006-12-18 Kombinacija derivatov triazina in inzulinskih stimulatorjev izločanja
ES06829703T ES2378469T3 (es) 2006-01-13 2006-12-18 Combinación de derivados de triazina y agentes estimulantes de la secreción de insulina
EA200801665A EA016649B1 (ru) 2006-01-13 2006-12-18 Комбинация производных триазина и стимуляторов секреции инсулина
CA2636837A CA2636837C (fr) 2006-01-13 2006-12-18 Combinaison de derives de triazine et de stimulateurs de secretion d'insuline
EP06829703A EP1971339B1 (fr) 2006-01-13 2006-12-18 Combinaison de derives de triazine et de stimulateurs de secretion d'insuline
PCT/EP2006/012182 WO2007079914A2 (fr) 2006-01-13 2006-12-18 Combinaison de derives de triazine et de stimulateurs de secretion d'insuline
US12/160,637 US8227465B2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators
KR1020087019388A KR20080091366A (ko) 2006-01-13 2006-12-18 트리아진 유도체 및 인슐린 분비 자극제의 조합물
AU2006334731A AU2006334731B2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin secretion stimulators
AT06829703T ATE540682T1 (de) 2006-01-13 2006-12-18 Kombination von triazin-derivaten und insulin- sekretionsstimulatoren
JP2008549780A JP5702911B2 (ja) 2006-01-13 2006-12-18 トリアジン誘導体およびインスリン分泌促進剤の組合せ
PL06829703T PL1971339T3 (pl) 2006-01-13 2006-12-18 Połączenie pochodnych triazyny i środków stymulujących wydzielanie insuliny
CNA2006800507984A CN101355949A (zh) 2006-01-13 2006-12-18 三嗪衍生物与胰岛素分泌促进剂的组合
ARP070100136A AR059030A1 (es) 2006-01-13 2007-01-12 Combinacion de derivados de triazina y estimuladores de la secrecion de insulina
IL192596A IL192596A (en) 2006-01-13 2008-07-02 Pharmaceutical preparations containing combinations of triazine derivatives and insulin secretion stimulants and their use in the preparation of medicines
ZA200806938A ZA200806938B (en) 2006-01-13 2008-08-12 Combination of triazine derivatives and insulin secretion stimulators
CY20121100133T CY1112674T1 (el) 2006-01-13 2012-02-08 Συνδυασμος παραγωγων τριαζινης και διεγερτων εκκρισης ινσουλινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0600342A FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.

Publications (2)

Publication Number Publication Date
FR2896157A1 FR2896157A1 (fr) 2007-07-20
FR2896157B1 true FR2896157B1 (fr) 2008-09-12

Family

ID=36648317

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0600342A Expired - Fee Related FR2896157B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.

Country Status (21)

Country Link
US (1) US8227465B2 (fr)
EP (1) EP1971339B1 (fr)
JP (1) JP5702911B2 (fr)
KR (1) KR20080091366A (fr)
CN (1) CN101355949A (fr)
AR (1) AR059030A1 (fr)
AT (1) ATE540682T1 (fr)
AU (1) AU2006334731B2 (fr)
BR (1) BRPI0620923A2 (fr)
CA (1) CA2636837C (fr)
CY (1) CY1112674T1 (fr)
DK (1) DK1971339T3 (fr)
EA (1) EA016649B1 (fr)
ES (1) ES2378469T3 (fr)
FR (1) FR2896157B1 (fr)
IL (1) IL192596A (fr)
PL (1) PL1971339T3 (fr)
PT (1) PT1971339E (fr)
SI (1) SI1971339T1 (fr)
WO (1) WO2007079914A2 (fr)
ZA (1) ZA200806938B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009326604B2 (en) * 2008-12-12 2014-07-31 Poxel S.A.S. Combination of insulin with triazine derivatives and its use for treating diabetes
FR2948028B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
RU2550798C2 (ru) * 2011-05-12 2015-05-10 Василий Иосифович Зоря Способ стимуляции секреции инсулина
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルＰｏｘｅｌ 駆出率が保持された心不全を治療する方法
KR20200130281A (ko) 2018-06-06 2020-11-18 메타반트 사이언시스 게엠베하 당뇨병과 만성 신장 질환을 갖는 대상체를 치료하는 방법
EP3806828A1 (fr) 2018-06-14 2021-04-21 Poxel Comprimé pelliculé comprenant un dérivé de triazine destiné à être utilisé dans le traitement du diabète
USD945167S1 (en) 2018-10-31 2022-03-08 Kimberly-Clark Worldwide, Inc. Paper sheet
JP7093473B2 (ja) * 2019-12-13 2022-06-29 住友ファーマ株式会社 製造性及び溶出性に優れた小型錠剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PT1133312E (pt) * 1999-06-21 2007-11-30 Lilly Co Eli Uso sinergístico de tiazolidinodionas com péptido 1 semelhante ao glucagon e os seus agonistas para tratar diabetes não insulino-dependente
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CA2397554C (fr) * 2000-01-21 2009-09-22 Novartis Ag Combinaisons comprenant des inhibiteurs de la dipeptidylpeptidase- iv et des agents antidiabetiques
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
ITFI20010126A1 (it) 2001-07-09 2003-01-09 Molteni & C Composizioni farmaceutiche per uso orale,contenenti,in combinazione,metformina e gliclazide
WO2003061643A1 (fr) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composition pharmaceutique permettant de surveiller le glucose dans le sang de patients souffrant de diabete de type 2
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
AU2004267955A1 (en) * 2003-09-02 2005-03-10 Prosidion Ltd. Combination therapy for glycaemic control

Also Published As

Publication number Publication date
KR20080091366A (ko) 2008-10-10
ES2378469T3 (es) 2012-04-12
US20100233255A1 (en) 2010-09-16
FR2896157A1 (fr) 2007-07-20
AU2006334731A1 (en) 2007-07-19
CA2636837C (fr) 2013-12-10
CN101355949A (zh) 2009-01-28
WO2007079914A2 (fr) 2007-07-19
ZA200806938B (en) 2010-02-24
IL192596A (en) 2015-07-30
JP5702911B2 (ja) 2015-04-15
BRPI0620923A2 (pt) 2011-11-29
AR059030A1 (es) 2008-03-12
EP1971339B1 (fr) 2012-01-11
CY1112674T1 (el) 2016-02-10
EA200801665A1 (ru) 2008-12-30
CA2636837A1 (fr) 2007-07-19
JP2009523139A (ja) 2009-06-18
WO2007079914A3 (fr) 2007-09-07
PT1971339E (pt) 2012-02-20
IL192596A0 (en) 2009-09-22
SI1971339T1 (sl) 2012-07-31
AU2006334731B2 (en) 2012-06-21
DK1971339T3 (da) 2012-02-20
PL1971339T3 (pl) 2012-04-30
ATE540682T1 (de) 2012-01-15
US8227465B2 (en) 2012-07-24
EA016649B1 (ru) 2012-06-29
EP1971339A2 (fr) 2008-09-24

Similar Documents

Publication Publication Date Title
FR2896157B1 (fr) Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
BRPI0809795A2 (pt) "antagonistas do trpv1 e usos deste".
FR2896159B1 (fr) Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
BRPI0716365A2 (pt) "artigo odontolàgico"
AP2936A (en) Long term treatment of HIV-infection with TMC278
BRPI0716374A2 (pt) "dispositivos médicos"
FR2896160B1 (fr) Combinaison de derives de triazine et d'agonistes du ppar alpha.
UA12122S (uk) Набір кутових секційних меблів «тутті»
UA14758S (uk) Комплект м'яких меблів
UA12119S (uk) Набір м'яких меблів «тутті»
UA14383S (uk) Набір м'яких меблів «квадро»
UA13462S (uk) Ванна кутова «relax»
ITRA20050027A1 (it) Stopper brooch "stappali & spillali"
UA14417S (uk) Крісло м'яке
UA13155S (uk) Крісло м'яке
UA14422S (uk) Крісло м'яке
UA14421S (uk) Крісло м'яке
UA14420S (uk) Крісло м'яке
UA14419S (uk) Крісло м'яке
UA14418S (uk) Крісло м'яке
UA14425S (uk) Крісло м'яке
UA14416S (uk) Крісло м'яке
UA13166S (uk) Крісло м'яке
UA13165S (uk) Крісло м'яке
UA13162S (uk) Крісло м'яке

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20220905